Patritumab deruxtecan induces immunogenic cell death., PMID:40458967
Efficient Design of Affilin® Protein Binders for HER3., PMID:40429825
Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors., PMID:40408047
Ophthalmological manifestations and plasma markers of inflammation in Ebola survivors in post-treatment era., PMID:40301432
HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway., PMID:40290122
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors., PMID:40178042
Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability., PMID:40108093
Emerging importance of HER3 in tumorigenesis and cancer therapy., PMID:40087402
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734
HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials., PMID:39995133
Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth., PMID:39984637
Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing., PMID:39948369
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma., PMID:39937426
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan., PMID:39931207
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer., PMID:39908431
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb., PMID:39757718
Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis., PMID:39754977
PlexinD1 is a driver and a therapeutic target in advanced prostate cancer., PMID:39748059
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas., PMID:39572979
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers., PMID:39495173
A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells., PMID:39485069
Antitumor activity of PAbs generated by immunization with a novel HER3-targeting protein-based vaccine candidate in preclinical models., PMID:39479017
Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling., PMID:39393543
Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation., PMID:39392382
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate., PMID:39128771
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance., PMID:39098760
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases., PMID:39094301
HER3 receptor and its role in the therapeutic management of metastatic breast cancer., PMID:39020378
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response., PMID:38992028
Long road towards effective HER3 targeting in breast cancer., PMID:38885540
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study., PMID:38823410
Trans-activating mutations of the pseudokinase ERBB3., PMID:38806620
Inhibition of EGFR/ErbB does not protect against C. difficile toxin B., PMID:38798529
HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?, PMID:38760830
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study., PMID:38748939
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors., PMID:38632563
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer., PMID:38605180
Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy., PMID:38441358
Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas., PMID:38428737
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors., PMID:38414979
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer., PMID:38369520
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC., PMID:38369013
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer., PMID:38339127
ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature., PMID:38306015
The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study., PMID:38231075
ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension., PMID:38214194
The novel antibody fusion protein rhNRG1-HER3i promotes heart regeneration by enhancing NRG1-ERBB4 signaling pathway., PMID:38150867
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target., PMID:37898642
Clinicopathological significance of concurrent ErbB receptor expression in human meningioma., PMID:37719042
For research use only. Not for human or drug use.
